Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Soared Today

By Keith Speights - Jun 2, 2021 at 4:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors cheered the company's progress with its COVID-19 vaccine program.

What happened

Shares of Novavax (NVAX 3.45%) soared 17.8% on Wednesday. The big jump came after the company stated that it would soon announce data from a U.S. phase 3 study of COVID-19 vaccine NVX-CoV2373 and is on track to hit its production goals for the vaccine.

So what

What does an impending announcement of late-stage results for NVX-CoV2373 really mean for the biotech stock? The sooner Novavax reports those results, the sooner it will be able to complete its submission to the Food and Drug Administration for Emergency Use Authorization (EUA) for its vaccine.

Healthcare professional holding a vaccine vial and a syringe.

Image source: Getty Images.

Novavax had hoped to file for EUA in the second quarter of 2021. However, the company revealed in its first-quarter update that the submission would slip into the third quarter. Assuming that Novavax is able to wrap up its U.S. late-stage study soon, it could potentially win EUA in the early part of the third quarter rather than later in the quarter.

Raw-material shortages have been a challenge for Novavax. But its chief commercial officer, John Trizzino, said in the Jefferies Virtual Healthcare Conference on Tuesday that the company is confident that it will be able to achieve its manufacturing goals, which include producing 100 million doses per month by the end of the third quarter and 150 million doses per month by the end of the fourth. 

Now what

Investors will have to continue waiting on Novavax's EUA filing for now. The good news is that earlier results from the company's late-stage study conducted in the U.K. were very positive and should bode well for its U.S. results. Novavax already has several major supply deals in place for its COVID-19 vaccine, including an agreement to supply 100 million doses to the U.S. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Jefferies Financial Group Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$43.76 (3.45%) $1.46

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
403%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.